Enterprise generative AI refers to the use of generative AI technologies within organizations to improve innovation, productivity, decision-making, and business processes. In pharmaceuticals, enterprise generative AI can support research, accelerate knowledge discovery, analyze complex information, assist scientists, and identify practical opportunities for innovation while creating new sources of business value.

Successful generative AI adoption requires a clear business strategy, strong data foundations, appropriate governance, responsible AI practices, technology infrastructure, and employee readiness. Large enterprises should prioritize high-value use cases, establish effective risk controls, continuously evaluate outcomes, and move beyond isolated experiments toward scalable applications that deliver measurable business benefits.

Enterprise AI transformation helps organizations progress from small-scale experimentation to structured, scalable implementation by connecting AI initiatives with strategic business objectives. It involves identifying valuable use cases, integrating AI into existing workflows, establishing governance, measuring performance, and continuously improving solutions so that experimentation translates into productivity gains, better decisions, and measurable business impact.

Pharmaceutical companies can use enterprise generative AI to summarize scientific literature, analyze large volumes of information, support research activities, generate insights, and assist knowledge-intensive workflows. It can also improve decision-making by making relevant information easier to access while helping teams automate repetitive tasks, enhance productivity, and improve operational efficiency across the enterprise.

Enterprises can convert generative AI investments into measurable value by selecting use cases according to business priorities, establishing clear success metrics, strengthening data and governance capabilities, and integrating AI into existing processes. Effective generative AI adoption also requires responsible experimentation, continuous performance measurement, employee training, and scaling solutions that demonstrate tangible productivity or business outcomes.

GlaxoSmithKline’s generative AI journey demonstrates the importance of exploring the technology while maintaining a strong focus on practical enterprise applications and business value. Organizations can learn to move beyond hype, evaluate emerging opportunities thoughtfully, build capabilities around innovation and data science, and progressively identify use cases where generative AI can create meaningful impact.